Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

Completed · Phase 2 · Has a placebo group

Conditions studied: Skin Aging

In brief

This study will confirm the efficacy and safety of a single topical administration of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines

Key facts

Study ID

NCT01940991

Run by

Revance Therapeutics, Inc.

People needed

82

Starts

2013-08-01

Expected to finish

2013-11-01

Last updated by the study team

2014-01-31

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Moderate to severe crow's feet lines
• Female or male, 18 to 65 years of age and in good general health
• Women of childbearing potential (WOCBP) must agree to use an effective method of birth control during the course of the study

You may not qualify if…

• Any neurological condition that may place the subject at increased risk with exposure to Botulinum Toxin Type A
• Muscle weakness or paralysis, particularly in the area receiving study treatment
• Active skin disease or irritation at the treatment area
• Deep dermal scarring, or inability to smooth out the crow's feet lines to be treated by manually spreading the skin apart
• Treatment with Botulinum Toxin Type A for crow's feet lines in the last 6 months or 3 months anywhere in the body

Where it is running

• Dermatology Research Institute — Coral Gables, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.